ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?
The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
In a Hole in the Budget There Lived a KOL
Not a nasty, dirty, wet hole, nor yet a humble one. This was a suite at the Four Seasons, with
The Problem with Markov Models
Markov models have become a default tool in drug development, used for modeling disease progression, treatment outcomes, and cost-effectiveness. While
AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead
Artificial intelligence has had a profound decade in biotech, advancing from a promising academic endeavor to a critical driver of
The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis
Optimism bias, the cognitive tendency to overestimate the likelihood of favorable outcomes and underestimate risks, is a pervasive issue in
The Problem with Biotech’s Love Affair with Academia
Biotech and academia are the original odd couple. One is driven by bold bets on untested science and the hope
The Problem with “Trendy Science” in Biotech: Chasing the Next Big Thing
Biotech is the land of promise—and peril. Every few years, a new scientific breakthrough takes center stage, drawing billions
Corporate Venture Funds and Strategic Partnerships: Friends, Benefactors, or Frenemies?
For biotech startups, corporate venture funds (CVCs) are often painted as a dream come true—cash with benefits. You get
The Ethics of Failure: The Uncomfortable Bedfellow
The Ethics of Failure: Biotech’s Uncomfortable Bedfellow
Failure is biotech’s least glamorous partner. It doesn’t show up
The Meeting That Achieved Nothing—and Why That’s Sometimes Okay
Modern corporate life has evolved into a peculiar form of theatre: every actor dressed in Uniqlo smart casual, each line